Drug manufacturer Johnson & Johnson’s decision to end voluntary 340B drug discounts on orphan drugs to more than 1,000 rural hospitals at the end of this year “will make it even harder for patients to access drugs they desperately need,” U.S. Rep. Peter Welch (D-Vt.) said yesterday.
Welch serves on the U.S. House Energy and Commerce Committee which has jurisdiction over the 340B program. He has been a long-time advocate for 340B providers and has co-sponsored bipartisan legislation since 2016 to require drug manufacturers to offer 340B pricing on orphan drugs when the medicines are used for common conditions.
Drug manufacturer Johnson & Johnson’s decision to end voluntary 340B drug discounts on orphan drugs to more than 1,000 rural hospitals at the end of this year “will make it even harder for patients to access drugs they desperately need,” U.S. Rep. Peter Welch (D-Vt.) said yesterday.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
